AnGes completed the acqusiition of EmendoBio from OrbiMed Advisors and Takeda Ventures for $250m.

AnGes, a commercial stage Japanese biopharmaceutical company, completed the acqusiition of EmendoBio, a biotechnology company, from private equity firms, OrbiMed Advisors and Takeda Ventures for $250m. “This transaction underscores the potential of EmendoBio’s novel technology platforms, the promise of our product candidates, and the value that our employees, strategic partners and founding investors, OrbiMed and Takeda Ventures, Inc. have created within the company. The alliance with AnGes brings new resources and synergies to our operations that will accelerate product development, partnerships and commercial opportunities in the years ahead," David Baram, EmendoBio President and CEO.